FDA Grants New Indication to Xarelto to Reduce Major CV Events

The FDA granted a new indication to rivaroxaban (Xarelto, Janssen Pharmaceuticals) to reduce the risk for major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD).